Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TerrAscendTSNDF 38 Days Sales Outstanding is 19.90 as of Jun. 2026, which is 16% below its 10-year median of 23.78. GuruFocus rates TSNDF with a GF Score™ of 38/100 and a GF Value™ of $0.76 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 945 Drug Manufacturers companies, TerrAscend ranks better than 93.97% on this metric.
TerrAscend's average Accounts Receivable for the
three
months ended in Jun. 2026 was $14.6 Mil. TerrAscend's Revenue for the
three
months ended in Jun. 2026 was $67.1 Mil.
Hence, TerrAscend's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 19.90.
The historical rank and industry rank for TerrAscend's Days Sales Outstanding or its related term are showing as below:
TSNDF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.08 Med: 23.78 Max: 290.96
Current: 21.89
During the past 10 years, TerrAscend's highest Days Sales Outstanding was 290.96. The lowest was 19.08. And the median was 23.78.
TSNDF's Days Sales Outstanding is ranked better than 93.97% of 945
companies
in the Drug Manufacturers industry
Industry Median: 71.73
vs TSNDF: 21.89
TerrAscend's Days Sales Outstanding
declined
from Jun. 2025 (26.29) to Jun. 2026 (19.90).
TerrAscend (OTCPK:TSNDF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
TerrAscend Days Sales Outstanding Related Terms
TerrAscend Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for TerrAscend's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TerrAscend Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TerrAscend's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where TerrAscend's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TerrAscend (TSNDF) has a Days Sales Outstanding of 19.90 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on TerrAscend and its competitors. This is 16% below median its historical median of 23.78. Over the past decade, TerrAscend's Days Sales Outstanding has ranged from 19.08 to 290.96. According to the industry distribution chart, TerrAscend ranks #57 out of 945 companies in the Drug Manufacturers industry, placing it in the top 6%.
Is TerrAscend's Days Sales Outstanding too high?
TerrAscend's current Days Sales Outstanding of 19.90 is 16% below median its 10-year median of 23.78. Over the past 10 years, this metric has ranged from a low of 19.08 to a high of 290.96. The Drug Manufacturers industry median Days Sales Outstanding is 71.73. TerrAscend's value of 19.90 is 72.3% below this industry median. Based on the distribution chart, TerrAscend ranks #57 out of 945 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TerrAscend has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TerrAscend ranks #57 out of 945 companies for Days Sales Outstanding. This places TerrAscend in the top 6% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.73. TerrAscend's value of 19.90 is 72.3% below this benchmark. Historically, TerrAscend's own Days Sales Outstanding has ranged from 19.08 to 290.96 over the past decade. While the company's 10-year median is 23.78 vs. the industry median of 71.73, TerrAscend has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.73, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TerrAscend's current Days Sales Outstanding of 19.90 is 72.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on TerrAscend and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TerrAscend's current Days Sales Outstanding is 19.90, which is 16% below median its own 10-year median of 23.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.76, compared to a current price of $0.62 — trading 19.1% below its estimated fair value. The current Days Sales Outstanding is 19.90, which is 16% below median its 10-year median of 23.78 and 72.3% below the Drug Manufacturers industry median of 71.73. TerrAscend's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For TerrAscend (TSNDF), the current Days Sales Outstanding is 19.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TerrAscend (TSNDF) Overvalued in 2026?
Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued.
The current stock price of $0.62 is trading 19.1% below its estimated GF Value™ of $0.76.
GuruFocus considers TerrAscend to be Modestly Undervalued.
Key valuation signals for TSNDF:
Days Sales Outstanding: 19.90 (16% below median its 10-year median of 23.78)
GF Value™: $0.76 vs. price of $0.62 (19.1% below fair value)
Industry Position: 72.3% below the Drug Manufacturers median (#57 of 945)
No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
38GF Score
Get the complete analysis for TSNDF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNDF has been successfully added to your 
